Observational studyJournal of global health2026
Demographics, clinical features, and comorbidities of high-altitude polycythaemia: a multicentre, retrospective, observational study.
Observational study in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High altitude polycythaemia (HAPC) has posed a major burden due to its high prevalence and multisystem involvement among highlanders, but clinical data on HAPC is scarce. We aimed to describe the clinical characteristics of patients with HAPC in China. Methods: Adult patients diagnosed with HAPC in five hospitals of China between August 2012 to May 2024 were retrospectively enrolled. We analysed information including demographics, living altitude, haemoglobin concentration (Hb) and comorbidities, and fitted restricted cubic splines models with multivariable adjustments to investigate the relationship between age, altitude and Hb. Results: A total of 1098 HAPC patients were included and 97 individuals of them did not provide information on ethnicity. Of the remaining 1001 participants, 93% were native Tibetans. The median Hb showed a significant difference (P < 0.0001) between male (21.9 g/dL, interquartile range (IQR) = 21.4-22.9 g/dL) and female patients (19.6 g/dL, IQR = 19.2-20.8 g/dL), and was slightly higher in Tibetans than Han migrants, especially in females (19.6 g/dL, IQR = 19.2-20.7 g/dL vs. 19.3 g/dL, IQR = 19.2-19.5 g/dL) (P = 0.198). Restricted cubic splines models revealed Hb exhibited a positive linear correlation with altitude (P-overall = 0.027, P-nonlinear = 0.291), with a rate of 0.3g/dL/1000 m of elevation, whereas no significant relationship with age (P-overall = 0.974, P-nonlinear = 0.860). The commonest comorbidities were hypertension (18.5%) and pneumonia (17.6%). Besides, heart failure (P < 0.001), chronic airway disease (P = 0.018) and pulmonary heart disease (P < 0.001) were more prominent in females while liver disease (P = 0.079) was more frequent in males. Conclusions: This study suggests a much higher proportion of HAPC in native Tibetans, and the Hb in HAPC patients remains significant gender-specific and altitude-dependent variations. Moreover, in addition to hypertension and pneumonia, gender-specific comorbidity surveillance should pay attention to digestive system disease in male HAPC patients and cardiopulmonary system disease in female HAPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.